BioAge Labs (NASDAQ:BIOA) Sets New 52-Week High – Time to Buy?

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price reached a new 52-week high on Monday . The company traded as high as $25.80 and last traded at $25.4950, with a volume of 37788 shares trading hands. The stock had previously closed at $25.10.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on BIOA shares. Needham & Company LLC began coverage on shares of BioAge Labs in a research note on Friday, March 27th. They issued a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. BTIG Research began coverage on BioAge Labs in a report on Wednesday, May 13th. They set a “buy” rating and a $40.00 target price on the stock. Citigroup increased their price target on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and an average price target of $43.50.

BioAge Labs Price Performance

The business has a 50-day simple moving average of $18.68 and a two-hundred day simple moving average of $18.34. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -10.47 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.The company had revenue of $2.77 million during the quarter. As a group, equities analysts anticipate that BioAge Labs, Inc. will post -2.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

Several hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its position in BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares during the period. Octagon Capital Advisors LP raised its position in shares of BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares during the period. Vanguard Group Inc. raised its position in shares of BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of BioAge Labs during the 4th quarter worth about $13,892,000. Finally, Geode Capital Management LLC lifted its stake in shares of BioAge Labs by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after buying an additional 28,646 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.